Pharmacotherapy of cervical cancer

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 12, 2010, Pages 2059-2075

  Legge, Francesco ^a,b   Fuoco, Gilda ^a   Lorusso, Domenica ^b   Lucidi, Alessandro ^a   Borriello, Maddalena ^a   Pisconti, Salvatore ^c   Scambia, Giovanni ^b   Ferrandina, Gabriella ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c Oncology Unit   (Italy)

Author keywords

Cervical cancer; Chemotherapy; Pharmacotherapy; Target based therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; LAPATINIB; METHOTREXATE; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMETREXED; SORAFENIB; SUNITINIB; TIRAPAZAMINE; TOPOTECAN; VINBLASTINE; ANTINEOPLASTIC AGENT;

ACNE; ADJUVANT THERAPY; ADVANCED CANCER; ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FISTULA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTHERMIC THERAPY; INFECTION; LAPAROSCOPIC SURGERY; LEUKOPENIA; LUNG EMBOLISM; LYMPH NODE DISSECTION; LYMPHOCYTOPENIA; MEDICAL LITERATURE; MEDICAL SOCIETY; METABOLIC DISORDER; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OVERALL SURVIVAL; PELVIS LYMPH NODE; POSTOPERATIVE COMPLICATION; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; QUALITY OF LIFE; RADIATION DOSE; RECURRENT CANCER; REVIEW; SKIN TOXICITY; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT FISTULA; UTERINE CERVIX CANCER; UTERINE CERVIX CONIZATION; VOMITING; ADJUVANT CHEMOTHERAPY; CANCER STAGING; FEMALE; GYNECOLOGIC SURGERY; PATHOLOGY; SECONDARY; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE; UTERINE CERVICAL NEOPLASMS;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 77954811847     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.493556     Document Type: Review

References (101)

1. Thun MJ, DeLancey JO, Center MM, et al. The global burden of cancer: priorities for prevention. Carcinogenesis 2010;31(1):100-110
2. Long HJ III. Management of metastatic cervical cancer: review of the literature. J Clin Oncol 2007;25:2966-2974
3. Tewari KS, Monk BJ. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Semin Oncol 2009;36(2):177-180
4. Serkies K, Jassem J. Chemotherapy in the primary treatment of cervical carcinoma. Crit Rev Oncol Hematol 2005;54:197-208
5. Ercoli A, Iannone V, Legge F, et al. Advances in surgical management of cervical cancer. Min Ginecol 2009;61(3):227-237
6. Green JA, Kirwan JJ, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix [review]. Cochrane Database Syst Rev 2009;4:1-52
7. Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer 2003;39(17):2470-2486
8. Ferrandina G, Legge F, Fagotti A, et al. Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome, and prognostic measures. Gynecol Oncol 2007;107(1 Suppl 1):S127-32
9. Dargent D, Martin X, Sacchettoni A, Mathevet P. Laparoscopic vaginal radical trachelectomy: a treatment to preserve the fertility of cervical carcinoma patients. Cancer 2000;88:1877-1882
10. Landoni F, Parma G, Peiretti M, et al. Chemoconization in early cervical cancer. Gynecol Oncol 2007;107:S125-S2
11. Maneo A, Chiari S, Bonazzi C, Mangioni C. Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer. Gynecol Oncol 2008;111:438-443
12. Rosa DD, Medeiros LR, Edelweiss MI, et al. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev 2009;3:CD005342
13. Rogers L, Siu SS, Luesley D, et al. Adjuvant radiotherapy and chemoradiation after surgery for cervical cancer. Cochrane Database Syst Rev 2009;4:CD007583
14. Peters WA III, Liu PY, Barrett RJ II, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18(8):1606-1613
15. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340(15):1154-1161
16. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340(15):1137-1143
17. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;15:1144-1153
18. Whitney CW, Sause W, Bundt BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB- IVA carcinoma of the cervix with negative para-aortic lymph nodes. A Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol 1999;17:1339-1348
19. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001;358:781-786
20. Vale C, Tierney JF, Stewart LA, et al. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. J Clin Oncol 2008;26(35):5802-5812
21. Wong LC, Ngan HY, Cheung AN, et al. Chemoradiation and adjuvant chemotherapy in cervical cancer. J Clin Oncol 1999;17(7):2055-2060
22. Available from: www.clinicaltrials.org
23. Duenas-Gonzalez A, Zarba JJ, Alcedo JC, et al. A Phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix. Meeting abstracts. J Clin Oncol 2009;27:18S
24. Lanciano R, Calkins A, Bundy BN, et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23(33):8289-8295
25. Domingo E, Lorvidhaya V, de Los Reyes R, et al. Capecitabine-based chemoradiotherapy with adjuvant capecitabine for locally advanced squamous carcinoma of the uterine cervix: phase II results. Oncologist 2009;14(8):828-834
26. Bhatt ML, Matin A, Srivastava MC, et al. Evaluation of gemcitabine versus cisplatinum as an adjunct to radiotherapy in locally advanced carcinoma uterine cervix. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):16012
27. Lorvidhaya V, Chitapanaraux I, Sangruchi S, et al. Concurrent mytomicin C. 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcionoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys 2003;55(5):1226-1232
28. Benedetti-Panici P, Greggi S, Scambia G, et al. Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Eur J Cancer 1998;34(3):341-346
29. Buda A, Fossati R, Colombo N, et al. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol 2005;23(18):4137-4145
30. Basile S, Angioli R, Manci N, et al. Gynecological cancers in developing countries: the challenge of chemotherapy in low-resources setting. Int J Gynecol Cancer 2006;16(4):1491-1497
31. Eddy GL, Manetta A, Alvarez RD, et al. Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study. Gynecol Oncol 1995;57(3):412-416
32. Chang TC, Lai CH, Hong JH, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. J Clin Oncol 2000;18(8):1740-1747
33. Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez A, et al. A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma. Ann Oncol 2001;12(4):541-547
34. Sugiyama T, Nishida T, Kumagai S, et al. Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Br J Cancer 1999;81(1):95-98
35. Benedetti-Panici P, Greggi S, Colombo A, et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol 2002;20(1):179-188
36. Gonzalez-Martin A, Gonzalez-Cortijo L, Carballo N, et al. The current role of neoadjuvant chemotherapy in the management of cervical carcinoma. Gynecol Oncol 2008;110(3 Suppl 2):S36-40
37. Eddy GL, Bundy BN, Creasman WT, et al. Treatment of ('bulky') stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the Gynecologic Oncology Group. Gynecol Oncol 2007;106(2):362-369
38. Lissoni AA, Colombo N, Pellegrino A, et al. A Phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study. Ann Oncol 2009;20(4):660-665
39. Resbeut M, Cowen D, Viens P, et al. Concomitant chemoradiation prior to surgery in the treatment of advanced cervical carcinoma. Gynecol Oncol 1994;54(1):68-75 (Pubitemid 24239411)
40. Jurado M, Martinez-Monge R, Garcla-Foncillas J, et al. A Pilot study of concurrent cisplatin, 5-fluorouracil, and external beam radiotherapy prior to radical surgery +/- intraoperative electron beam radiotherapy in locally advanced cervical cancer. Gynecol Oncol 1999;74(1):30-37
41. Mancuso S, Smaniotto D, Benedetti Panici P, et al. Phase I-II trial of preoperative chemoradiation in locally advanced cervical carcinoma. Gynecol Oncol 2000;78(3 Pt 1):324-328
42. Houvenaeghel G, Lelievre L, Rigouard AL, et al. Residual pelvic lymph node involvement after concomitant chemoradiation for locally advanced cervical cancer. Gynecol Oncol 2006;102(1):74-79
43. Lerouge D, Touboul E, Lefranc JP, et al. Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages IB2, IIA, and IIB with proximal parametrial invasion. Cancer Radiother 2004;8(3):168-177
44. Classe JM, Rauch P, Rodier JF, et al. Groupe des Chirurgiens de Centre de Lutte Contre le Cancer. Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer). Gynecol Oncol 2006;102(3):523-529
45. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004;22(5):872-880 (Pubitemid 41103599)
46. Chassagne D, Sismondi P, Horiot JC, et al. A glossary for reporting complications of treatment in gynecological cancers. Radiother Oncol 1993;26(3):195-202
47. Keys HM, Bundy BN, Stehman FM, et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol 2003;89(3):343-353
48. Thigpen T, Shingleton H, Homesley H, et al. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Crit Rev Oncol Hematol 2005;54(3):197-208
49. Bonomi P, Blessin JA, Stehman FB, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 1985;3(8):1079-1085
50. Weiss GR, Green S, Hannigan EV, et al. A Phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group Study. Gynecol Oncol 1990;39(3):332-336
51. Arseneau J, Blessing JA, Stehman FB, McGehee R. A Phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group Study). Invest New Drugs 1986;4(2):187-191
52. McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group Study. J Clin Oncol 1996;14(3):792-795
53. Kudelka AP, Winn R, Edwards CL, et al. An update of a Phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 1997;8(7):657-661
54. Curtin JP, Blessing JA, Webster KD, et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2001;19(5):1275-1278
55. Verschraegen CF, Levy T, Kudelka AP, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997;15:625-631 (Pubitemid 27074231)
56. Look KY, Blessing JA, Levenback C, et al. A phase II study of CPT-11 in recurrent squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 1998;70(3):334-338 (Pubitemid 28473631)
57. Lhomme C, Fumoleau P, Fargeot P, et al. Results of a European organization for research and treatment of cancer/early clinical studies group phase II trial of first line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1999;17:3136-3142
58. Bookman MA, Blessing JA, Hanjani P, et al. Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000;77:446-449
59. Muderspach LI, Blessing JA, Levenback C, Moore JL Jr. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 2001;81:213-215 (Pubitemid 32424163)
60. Morris M, Brader KR, Levenback C, et al. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1998;16:1094-1098 (Pubitemid 28108745)
61. Lhomme C, Vermorken JB, Mickiewicz E, et al. Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynecological Cancer Cooperative Group Study. Eur J Cancer 2000;36(2):194-199
62. Muggia FM, Blessing JA, Waggoner S, et al. Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a gynaecologic Oncology Group Study. Gynecol Oncol 2005;96(1):108-111
63. Sutton GP, Blessing JA, McGuire WP, et al. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group Study. Am J Obstet Gynecol 1993;168:805-807
64. Garcia AA, Blessing JA, Darcy KM, et al. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a Gynaecologic Oncology Group Study. Gynecol Oncol 2007;104(3):572-579
65. Rose PG, Blessing JA, Van le L, Waggoner S. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 1998;70(2):263-266
66. Rose PG, Blessing JA, Buller RE, et al. Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 2003;89(2):267-270
67. Rose PG, Blessing JA, Lele S, Abulafia O. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006;102(2):210-213
68. Miller DS, Blessing JA, Bodurka DC, et al. Evaluation of pemetrexed (Alymta, LY231514) as as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2008;110(1):65-70
69. Lorusso D, Ferrandina G, Pignata S, et al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol 2010;21(1):61-66
70. Omura GA, Blessing JA, Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 1997;15(1):165-171
71. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22:3113-3119
72. Long HJ III, Bundy BN, Grendys EC Jr, et al. Randomized Phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4626-4633
73. Monk BJ, Huang HQ, Cella D, Long HJ III. Gynecologic Oncology Group study. Quality of life outcomes from a randomized Phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23(21):4617-4625
74. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2009;27(28):4649-4655
75. Moore KN, Herzog TJ, Lewin S, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 2007;105(2):299-303
76. Mabuchi S, Morishige K, Fujita M, et al. The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy. Gynecol Oncol 2009;113(2):200-204
77. Saito I, Kitagawa R, Fukuda H, et al. A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Jpn J Clin Oncol 2010;40(1):90-93
78. Kuo Y, Blank S V , Kobrinsky B, et al. Oxaliplatin plus paclitaxel for recurrent and metastatic cervical cancer (CC): New York Cancer Consortium Trial P5840. Meeting abstracts. J Clin Oncol 2007;25:5549
79. Buxton EJ, Meanwell CA, Hilton C, et al. Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst 1989;81(5):359-361
80. Murad AM, Triginelli SA, Ribalta JC. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol 1994;12(1):55-59
81. Zanetta G, Fei F, Parma G, et al. Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer. Ann Oncol 1999;10(10):1171-1174
82. Stornes I, Mejlholm I, Jakobsen A. A Phase II trial of ifosfamide, 5-fluorouracil, and leucovorin in recurrent uterine cervical cancer. Gynecol Oncol 1994;55(1):123-125
83. Fanning J, Ladd C, Hilgers RD. Cisplatin, 5-fluorouracil, and ifosfamide in the treatment of recurrent or advanced cervical cancer. Gynecol Oncol 1995;56(2):235-238
84. Bloss JD, Blessing JA, Behrens BC, et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2002;20(7):1832-1837
85. Long HJ III, Monk BJ, Huang HQ, et al. Gynecologic Oncology Group. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 2006;100(3):537-543
86. Tanioka M, Katsumata N, Hirata T, et al. Secondary platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy. Meeting abstracts. J Clin Oncol 2009;27:5588
87. Moore DH, Tian C, Monk BJ, et al. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2010;116(1):44-49
88. Symonds R, Davidson S, Chan S, et al. SCOTCERV: a phase II trial of docetaxel and gemcitabine as second-line chemotherapy in cervical cancer. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):5548
89. Tiersten AD, Selleck MJ, Hershman DL, et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol 2004;92(2):635-638
90. Monk BJ, Willmott LJ, Sumner DA. Anti-angiogenesis agents in metastatic or recurrent cervical cancer. Gynecol Oncol 2010;116(2):181-186
91. Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2009;27(7):1069-1074
92. Monk BJ, Mas L, Zarba JJ, et al. A randomized Phase II study: Pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L +P) in advanced and recurrent cervical cancer (CC). Meeting abstracts. J Clin Oncol 2009;27:5520
93. Mackay HJ, Tinker A, Winquist E, et al. A Phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 2010;116(2):163-167
94. Del Campo JM, Prat A, Gil-Moreno A, et al. Update on novel therapeutic agents for cervical cancer. Gynecol Oncol 2008;110(3 Suppl 2):S72-6
95. Movva S, Rodriguez L, Arias-Pulido H, Verschraegen C. Novel chemotherapy approaches for cervical cancer. Cancer 2009;115:3166-3180
96. Available from: www.mito-group.it
97. Farley H, Sill M, Walker JL, et al. Phase II evaluation of cisplatin plus cetuximab in the treatment of recurrent and persistent cancers of the cervix: a limited access phase II study of the Gynecologic Oncology Group. Meeting abstracts. J Clin Oncol 2009;27:5521
98. Kurtz E, Besson D, Deslandres M, et al. Cetuximab (Ce) + topotecan (Tc) + cisplatin (Cp) for the treatment (Tt) of advanced cervix cancer (ACC): a phase II GINECO Trial. Meeting abstracts. J Clin Oncol 2008;26:5512
99. Goncalves A, Fabbro M, Lhomme C, et al. A Phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol 2008;108(1):42-46
100. Schilder RJ, Sill MW, Lee YC, Mannel R. A Phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer 2009;19(5):929-33 101.
101. Ferreira CG, Erlich F, Carmo CC, et al. Erlotinib (E) combined with cisplatin (C) and radiotherapy (RT) for patients with locally advanced squamous cell cervical cancer: A Phase II trial. Meeting abstracts. J Clin Oncol 2008;26:5511